2020 Autonomic Disorders Reading List, Learning Objectives, and CME

Reading List

Please click below to access the 2020 Autonomic Disorders reading list.

2020 Autonomic Disorders Reading List »

C-cert Activity Description

The Continuous Certification (C-cert) activities provide subspecialty learning and knowledge assessment to ensure that diplomates are staying up to date on the latest science, treatments, and therapeutics relating to their subspecialty. The annual activities include: 1) reading the subspecialty journal articles, and 2) taking and passing the 25-question online post-reading quiz to assess knowledge gained from the journal article content. 

Learning Objectives

Upon completion of this UCNS C-cert activity, participants will be able to:
  • More accurately accurately identify orthostatic hypotension with and without supine hypertension
  • Incorporate new strategies to better understand the autonomic nervous system, obtaining an accurate and adequate history and physical examination and to understand the long-term natural history of the processes that are involved
  • Incorporate new treatment modalities that will enhance and improve functionality of patients with autonomic dysfunction, particularly orthostatic hypotension, postural orthostatic tachycardia syndrome and inappropriate sinus tachycardia as well as other conditions that lead to syncope

Core Competencies

This UCNS C-cert activity covers the following core competency:
  • Medical Knowledge

AMA Credit Designation Statement

The American Academy of Neurology Institute designates this enduring material for a maximum of 11 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Medical Education (CME) Instructions

To claim CME credits, answer question 26 on the quiz to reflect the total time spent completing the required reading and online quiz. This question is not included in the scoring of the quiz. A passing score of 80% of higher is needed to meet C-cert requirements and receive CME credit. CME credit confirmation will be emailed within three weeks of passing the quiz.

ACCME Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Academy of Neurology Institute (AANI) and United Council for Neurologic Subspecialties. The AANI is accredited by the ACCME to provide continuing medical education for physicians.

Disclosures

The UCNS complies with all standards and policies of the ACCME, including identification and resolution of all conflicts of interest prior to the educational activity being delivered to learners. Accordingly, UCNS  planners, authors, and staff comply with the UCNS’s Conflicts of Interest Policy

Autonomic Disorders Certification Examination Committee Contributors


Paola Sandroni, MD, PhD, Mayo Clinic - Rochester

Disclosures: Nothing to disclose.

William P. Cheshire, MD, Mayo Clinic - Jacksonville
Disclosures: Received reimbursement from Wolters Kluwer for writing for UpToDate; Received research support in the form of travel reimbursement from Biohaven to attend research investigators’ meeting.

Elizabeth Coon, MD, Mayo Clinic – Rochester
Disclosures: Nothing to disclose.

Roy L. Freeman, MD, Beth Israel Deaconess Hospital
Disclosures: Received personal compensation and/or stock options for serving on scientific advisory boards of: Abide, Applied Therapeutics, Astellas, Aptinyx, Biogen, Biohaven, Cutaneous NeuroDiagnostics, GW Pharma, Ironwood, Lundbeck, MundiPharma, NeuroBo, Novartis, Pfizer, Regenacy, Spinifex, Toray, Theravance and Vertex; Holds stock or stock options for NeuroBo as chair of the scientific advisory board; Received research support from Biogen for quality control of skin biopsy data, from Theravance for trials and study for orthostatic hypotension trial. Received research support from Biohaven for trial of multiple system atrophy.

David S. Goldstein, MD, PhD, NINDS, NIH

Disclosures: Received research funding from the United States government.


Phillip A. Low, MD, FAAN, Mayo Clinic – Rochester
Disclosures: Received personal compensation from WR Medical for consultant services.

Peter Novak, MD, PhD, Brigham and Women's Faulkner Hospital

Disclosures: Received personal compensation as Advisor - independent contractor for Dysimmune Diseases Foundation. Member of Scientific Advisory Board for Endonovo Therapeutics. Received royalties for authored book, Autonomic Testing; Holds stock in Pfizer.    

Brian Olshansky, MD, University of Iowa Hospitals and Clinics
Disclosures: Received personal compensation from Boehringer Ingelheim, Lundbeck, Amarin, Sanofi-Aventis, and Respironics for consultant services.

Lauren Phillips, MD, UT Southwestern Medical School
Disclosures: Received personal compensation as a consultant for ACI Clinical - Neurology Endpoint Adjudication Committee; Received research support from NeuroNEXT (Network for Excellence in Neuroscience Clinical Trials) funded by National Institute of Health’s National Institute of Neurological Disorders and Stroke (NINDS) for project: Topirimate as a Disease Altering Therapy for role as  for Cryptogenic Sensory Peripheral Neuropathy (CSPN) [NN108 TopCSPN], role as site principal investigator; Received research support from Grifols Pharmaceuticals (Industry) for project: Dysautonomia International Title of Project: iSTAND: IVIG (Gamunex-C) Study of Treatment for Autoimmune Neuropathic Dysautonomia/Postural Tachycardia (POTS), Role: Co-Investigator.

Staff Contact

Bryan Hagerla, Continuous Certification Manager
[email protected]
(612) 928-6326